ATLN, DNA in pulmonary hypertension deal

Actelion (SWX:ATLN) will develop and co-promote its Tracleer bosentan endothelin receptor antagonist with Genentech (DNA) in the U.S. ATLN will receive an upfront payment of $35 million and additional...